Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheng Gao

Showing results (641-650 of 656) with videos related to

Pageof 66
Sort By:
Therapeutic Advances in Medical Oncology|November 1, 2021
Development of a risk classification system combining TN-categories and circulating EBV DNA for non-metastatic NPC in 10,149 endemic casesFo-Ping Chen, Li Lin, Jin-Hui Liang, et al.
ACS Medicinal Chemistry Letters|May 6, 2015
Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonistsChristine Yang, Jaume Balsells, Hong D Chu, et al.
RMD Open|June 28, 2024
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA studyPeter C Taylor, Georg Schett, Tom Wj Huizinga, et al.
Acta Pharmaceutica Sinica. B|August 15, 2022
<i>Morinda officinalis</i> oligosaccharides increase serotonin in the brain and ameliorate depression <i>via</i> promoting 5-hydroxytryptophan production in the gut microbiotaZheng-Wei Zhang, Chun-Sheng Gao, Heng Zhang, et al.
Frontiers in Pharmacology|May 22, 2020
Investigation of the Cellular Pharmacological Mechanism and Clinical Evidence of the Multi-Herbal Antiarrhythmic Chinese Medicine Xin Su NingYu-Ling Ma, Rou-Mu Hu, Xinchun Yang, et al.
Human Vaccines & Immunotherapeutics|May 5, 2026
Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trialsFaye Yu, Eugene Myshkin, Brandon Nguyen, et al.
BMJ (Clinical Research Ed.)|June 19, 2024
Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trialGuo-Ying Liu, Yan-Fang Ye, Yao-Fei Jiang, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|June 7, 2025
Efficacy and safety of Shuxuening injection in patients with unstable angina: a multicenter, randomized, placebo-controlled trialLintong Yu, Shiyi Tao, Qian Lin, et al.
BMJ (Clinical Research Ed.)|February 6, 2023
Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trialYan-Ping Mao, Shun-Xin Wang, Tian-Sheng Gao, et al.
BMJ (Clinical Research Ed.)|March 31, 2026
Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trialShun-Xin Wang, Ya-Lan Tao, Tian-Sheng Gao, et al.
Pageof 66

Showing results (641-650 of 656) with videos related to

Sort By:
Pageof 66
Therapeutic Advances in Medical Oncology|November 1, 2021
Development of a risk classification system combining TN-categories and circulating EBV DNA for non-metastatic NPC in 10,149 endemic casesFo-Ping Chen, Li Lin, Jin-Hui Liang, et al.
ACS Medicinal Chemistry Letters|May 6, 2015
Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonistsChristine Yang, Jaume Balsells, Hong D Chu, et al.
RMD Open|June 28, 2024
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA studyPeter C Taylor, Georg Schett, Tom Wj Huizinga, et al.
Acta Pharmaceutica Sinica. B|August 15, 2022
<i>Morinda officinalis</i> oligosaccharides increase serotonin in the brain and ameliorate depression <i>via</i> promoting 5-hydroxytryptophan production in the gut microbiotaZheng-Wei Zhang, Chun-Sheng Gao, Heng Zhang, et al.
Frontiers in Pharmacology|May 22, 2020
Investigation of the Cellular Pharmacological Mechanism and Clinical Evidence of the Multi-Herbal Antiarrhythmic Chinese Medicine Xin Su NingYu-Ling Ma, Rou-Mu Hu, Xinchun Yang, et al.
Human Vaccines & Immunotherapeutics|May 5, 2026
Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trialsFaye Yu, Eugene Myshkin, Brandon Nguyen, et al.
BMJ (Clinical Research Ed.)|June 19, 2024
Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trialGuo-Ying Liu, Yan-Fang Ye, Yao-Fei Jiang, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|June 7, 2025
Efficacy and safety of Shuxuening injection in patients with unstable angina: a multicenter, randomized, placebo-controlled trialLintong Yu, Shiyi Tao, Qian Lin, et al.
BMJ (Clinical Research Ed.)|February 6, 2023
Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trialYan-Ping Mao, Shun-Xin Wang, Tian-Sheng Gao, et al.
BMJ (Clinical Research Ed.)|March 31, 2026
Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trialShun-Xin Wang, Ya-Lan Tao, Tian-Sheng Gao, et al.
Pageof 66